Literature DB >> 21338111

Structure-activity relationships of cycloalkylamide derivatives as inhibitors of the soluble epoxide hydrolase.

In-Hae Kim1, Yong-Kyu Park, Bruce D Hammock, Kosuke Nishi.   

Abstract

Structure-activity relationships of cycloalkylamide compounds as inhibitors of human sEH were investigated. When the left side of amide function was modified by a variety of cycloalkanes, at least a C6 like cyclohexane was necessary to yield reasonable inhibition potency on the target enzyme. In compounds with a smaller cycloalkane or with a polar group on the left side of amide function, no inhibition was observed. On the other hand, increased hydrophobicity dramatically improved inhibition potency. Especially, a tetrahydronaphthalene (20) effectively increased the potency. When a series of alkyl or aryl derivatives of cycloalkylamide were investigated to continuously optimize the right side of the amide pharmacophore, a benzyl moiety functionalized with a polar group produced highly potent inhibition. A nonsubstituted benzyl, alkyl, aryl, or biaryl structure present on the right side of the cycloalkylamide function induced a big decrease in inhibition potency. Also, the resulting potent cycloalkylamide (32) showed reasonable physical properties.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338111      PMCID: PMC3517215          DOI: 10.1021/jm101431v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

1.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Authors:  K Node; Y Huo; X Ruan; B Yang; M Spiecker; K Ley; D C Zeldin; J K Liao
Journal:  Science       Date:  1999-08-20       Impact factor: 47.728

2.  Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Authors:  John D Imig; Xueying Zhao; Jorge H Capdevila; Christophe Morisseau; Bruce D Hammock
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

3.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Authors:  Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

4.  Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.

Authors:  In-Hae Kim; Fenton R Heirtzler; Christophe Morisseau; Kosuke Nishi; Hsing-Ju Tsai; Bruce D Hammock
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

5.  Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.

Authors:  Kevin R Smith; Kent E Pinkerton; Takaho Watanabe; Theresa L Pedersen; Seung Jin Ma; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

6.  Cytochrome P450 2C is an EDHF synthase in coronary arteries.

Authors:  B Fisslthaler; R Popp; L Kiss; M Potente; D R Harder; I Fleming; R Busse
Journal:  Nature       Date:  1999-09-30       Impact factor: 49.962

7.  Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.

Authors:  Oliver Jung; Ralf P Brandes; In-Hae Kim; Frank Schweda; Ronald Schmidt; Bruce D Hammock; Rudi Busse; Ingrid Fleming
Journal:  Hypertension       Date:  2005-02-07       Impact factor: 10.190

8.  Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

Authors:  Xueying Zhao; Tatsuo Yamamoto; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock; Janet Stewart; Jennifer S Pollock; David M Pollock; John D Imig
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

9.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.

Authors:  In-Hae Kim; Christophe Morisseau; Takaho Watanabe; Bruce D Hammock
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

10.  Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase.

Authors:  M F Moghaddam; D F Grant; J M Cheek; J F Greene; K C Williamson; B D Hammock
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

View more
  5 in total

1.  Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.

Authors:  Leila Karami; Ali Akbar Saboury; Elham Rezaee; Sayyed Abbas Tabatabai
Journal:  Eur Biophys J       Date:  2016-12-07       Impact factor: 1.733

2.  Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; In-Hee Lee; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

3.  Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase.

Authors:  In-Hae Kim; Kosuke Nishi; Takeo Kasagami; Christophe Morisseau; Jun-Yan Liu; Hsing-Ju Tsai; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2012-08-02       Impact factor: 2.823

Review 4.  Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.

Authors:  Amarjyoti Das Mahapatra; Rinku Choubey; Bhaskar Datta
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

Review 5.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.